[Expectations and developments in atypical antipsychotics].
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D048909:Diabetes Complications; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000139:chemically induced; D000077152:Olanzapine; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy; D015430:Weight Gain
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D003024:Clozapine; D006220:Haloperidol; D000077152:Olanzapine